CSV June 15, 2023 through June 15, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LEVOFLOXACI	ADDITIONAL R	*USP36–NF31*	4099	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First*	Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
N	EQUIREMENTS/*USP Reference Standards <11>*						*Supplement to USP37–NF32*	Levofloxacin Related Compound A RS: Change (*S*)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4-benzoxazine-6-carbocylic acid. to: (*S*)-9-Fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4]benzoxazine-6-carboxylic acid. AND Line 2 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Levofloxacin Related Compound B RS: Change (*S*)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4-benzoxazine-6-carbocylic acid. to: (*S*)-9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4]benzoxazine-6-carboxylic acid.
VENLAFAXINE HYDROCHLOR	ADDITIONAL REQUIREMENT	*USP36–NF31*	5551	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to*	Line 2 of Venlafaxine

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
IDE	S/*USP Reference Standards <11>*						*USP37–NF32*	Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. $C_{16}H_{25}NO_2$ 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl) cyclohexanol hydrochloride. $C_{16}H_{25}NO_2 \cdot HCl$ 299.84
STINGING NETTLE	COMPOSITION /*Content of Total Amino Acids*	*USP36–NF31*	1604	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
GENTAMICIN SULFATE	IM PURITIES/*Limit of Methanol*	*First Supplement to USP36–NF31*	5990	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	150 mg of hydrindantin, Line 11 of *Analysis*: Change Result = $(R_U/R_S) \times (C_S/C_U) \times D \times F \times 100$ to: Result = $(R_U/R_S) \times (C_S/C_U) \times D \times F$ AND Line 18 of *Analysis*: Change C_S = percentage of methanol in the *Standard solution* (% v/v) to: C_S = percentage of methanol in the *Standard solution* AND Line 23 of *Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change *F* = conversion factor, 0.001 g/mg to: *F* = conversion factor, 1000 mg/g
AMOXICILLIN	IMPURITIES/*Organic Impurities/Procedure*	*USP36–NF31*	2477	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Acceptance criteria*: Change [Note—The reporting limit is 0.03% of the amoxicillin peak from the *Standard solution*.] to: [Note—The reporting limit is 0.03 times the amoxicillin peak from the *Standard solution*.]
CLARITHROMYCIN EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 4*	*USP36–NF31*	3019	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Standard solution*: Change and *Medium*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(96:4). to: and *Medium* (4:96).
DIPHENHYDRAMINE HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP36–NF31*	3277	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *System suitability solution*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile phase*—Prepare a solution of acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the *Assay preparation* subsection: Add *System suitability solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								—Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer 1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								The flow rate is about 1 mL per minute. Chromatograph the *System suitability solution*, and record the peak responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the *Standard preparation*, and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal volumes, about 10 ?L, of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and measure the responses for the major peaks.
FLUPHENAZINE DECANOATE INJECTION	*Assay*	*USP36–NF31*	3639	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Standard preparation*: Delete (1:5) AND Line 8 of *Assay preparation*: Delete (1:5)
OLMESARTAN MEDOXOMIL	IMPURITIES/*Organic Impurities/Impurity Table*	*USP36–NF31*	4570	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2′-(2-trityl-1*H*-tetrazol-5-yl)biphenyl-4-yl)methyl)-1*H*-imidazole-5-carboxylate.
POWDERED GYMNEMA	IDENTIFICATION/*B. Thin-Layer Chromatography/ Chromatographic system*	*First Supplement to USP36–NF31*	5883	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of *Adsorbent*: Change 5m to: 5 µm
GLYCERYL DISTEARATE	ASSAY/*Procedure/ Chromatographic system*	*USP36–NF31*	2029	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Column temperature*: Change *Column temperature*: 40° to: *Temperatures Detector*: 40° *Column*: 40°
OXCARBAZEPINE	IMPURITIES/*Organic Impurities,*	*First Supplement to USP36–NF31*	6035	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 9 of Column 1 of *Table 3*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Procedure 2							Oxcarbazepine related compound E[g] to: Oxcarbazepine related compound E AND Delete footnote g
CEFDINIR CAPSULES	IM PUR ITIES/*Organic Impurities*/*Table 2*	*USP36–NF31*	2850	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 16 of Column 1: Change Cefdinir impurity 2[e] to: Cefdinir impurity 2[f] AND Row 21 of Column 1: Change Cefdinir impurity 3[e] to: Cefdinir impurity 3[f]
DIPHENHYDR AMINE HYDRO CHLORIDE CAPSULES	*Assay*	*USP36–NF31*	3276	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								System suitability solution, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diphenhydramine Hydrochloride*. to: *Mobile phase*—Prepare a solution of acetonitrile, water, and triethylamine (50: 50: 0.5), adjust with glacial acetic acid to a pH of 6.5, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								prep aration—Dissolve an accurately weighed quantity of USP Diphenhydramine Hydrochloride RS in water to obtain a solution having a known concentration of about 0.5 mg per mL. AND After the *Assay preparation* subsection: Add *System suitability solution*—Dissolve about 5 mg of benzophenone in 5 mL of acetonitrile, dilute with water to 100 mL, and mix. Transfer

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1.0 mL of this solution and 5 mg of diphenhydramine hydrochloride to a 10-mL volumetric flask, dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the *System suitability solution*, and record the peak

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								responses as directed for *Procedure*; the resolution, *R*, between the benzophenone and diphenhydramine peaks is not less than 2.0. Chromatograph replicate injections of the *Standard preparation*, and record the peak responses as directed for *Procedure*; the relative standard deviation is not more than 2.0%, and the tailing factor for the diphenhydramine hydrochloride peak is not more than 2.0. AND

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diphenhydramine Hydrochloride*. to: Separately inject equal volumes, about 10 ?L, of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
FELBAMATE TABLETS	IMPURITIES/*Organic Impuri*	*USP36–NF31*	3537	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Resolution*: Change NMT 2

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ties/System suitability/Suitability requirements							to: NLT 2
MOXIFLOXACIN OPHTHALMIC SOLUTION	*Related compounds*	*USP36–NF31*	4414	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Row 1 of Column 3 of *Table 2*: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin AND Row 1 of Column 3 of *Table 3*: Change Relative Retention Time vs. Moxifloxacin to: Relative Retention vs. Moxifloxacin
VENLAFAXINE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference*	*USP36–NF31*	5554	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 2 of Venlafaxine Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Standards <11>							RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. $C_{16}H_{25}NO_2$ 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl) cyclohexanol hydrochloride. $C_{16}H_{25}NO_2 \cdot HCl$ 299.84
POWDERED STINGING NETTLE	COMPOSITION */Content of Total Amino Acids*	*USP36–NF31*	1606	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Reagent solution*: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MEPROBAMATE TABLETS	ASSAY/ *Procedure*	*First Supplement to USP36–NF31*	6015	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 4 of *Standard solution*: Change Dissolve in 30% of the final flask volume, and dilute with water to volume. to: Dissolve in 30% of the final flask volume of acetonitrile, and dilute with water to volume.
BETAMETHASONE SODIUM PHOSPHATE	*Identification/B. Thin-Layer Chromatographic Identification Test <201>*	*USP36–NF31*	2645	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Test solution*: Change 1 mg per mL. to: 1 mg per mL in methanol.
DACARBAZINE FOR INJECTION	*USP Reference standards <11>*	*USP36–NF31*	3137	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of USP Dacarbazine Related Compound B RS: Change $C_4H_3N_5O$ 137.10 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$C_4H_3N_5O \cdot H_2O$ 155.12
EDETATE DISODIUM	ASSAY/ *Procedure*	*USP36–NF31*	3370	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 5: Delete *Titrimetric system* (See *Titrimetry* <541>.) *Mode*: Direct titration *Titrant*: 0.1 N sodium hydroxide VS *Endpoint detection*: Visual
LAMOTRIGINE TABLETS	PERFORMANCE TESTS/ *Dissolution* <711>/*Test 1*	*USP36–NF31*	4056	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 3 of *Standard solution*: Change 0.028 µg/mL to: 0.028 mg/mL
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS	IMPURITIES/*Organic Impurities*/*Table 2*	*USP36–NF31*	5438	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present). AND Footnote d: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual unspecified impurity if present).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present).
PURIFIED GYMNEMA EXTRACT	COMPOSITION */Content of Gymnemic Acids*	*First Supplement to USP36–NF31*	5884	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 1 of *Acceptance criteria*: Change 90%–110% of the labeled amount to: 90.0%–110.0% of the labeled amount on the dried basis
SODIUM HYDROXIDE	ASSAY/ *Procedure*	*USP36–NF31*	2203	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Line 11 of *Analysis*: Change = volume of *Titrant* consumed by the *Sample* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the first endpoint (mL) to: = volume of *Titrant* consumed by the *Sample* to the second endpoint (mL)
CLARITHROMYCIN FOR ORAL SUSPENSION	ASSAY/ *Procedure*	*USP36–NF31*	3018	26-Jul-2013	1-Aug-2013	*USP38–NF33*	*First Supplement to USP37–NF32*	Change the subsection head *Buffer*: to: *Buffer A*: AND After the *Buffer A* subsection: Add *Buffer B*: 0.067 M dibasic potassium phosphate AND Line 1 of *Mobile phase*: Change Methanol and *Buffer* to: Methanol and *Buffer A*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 4 of *Sample stock solution*: Change with the aid of 330 mL of *Buffer*, to a 1000-mL volumetric flask containing 50 mL of *Buffer*. to: with the aid of 330 mL of *Buffer B*, to a 1000-mL volumetric flask containing 50 mL of *Buffer B*.
PENTAZOCINE INJECTION	*Chemical Information*	*USP36–NF31*	4734	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Remove all chemical information.
POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES	*Assay*	*USP36–NF31*	4838	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample solution*.
SELEGILINE HYDROCHLORIDE TABLETS	*Dissolution <711>*	*USP36–NF31*	5120	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Chromatographic system*: Change Chromatograph the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution, and record the peak responses. to: The flow rate is 1.0 mL/min. Chromatograph the *Standard solution*, and record the peak responses.
BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS	METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES	*USP36–NF31*	619	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change the section title *Method 6—Postcolumn DABS-Cl Derivatization General Principle* to: *Method 6—Precolumn DABS-Cl Derivatization General Principle*
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION	*Assay*	*USP36–NF31*	5558	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Mobile phase*: Change 0.01 M to: 0.01 N

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 7 of *Assay preparation*: Change 10-mL to: 100-mL
AMITRIPTYLINE HYDROCHLORIDE TABLETS	IDENTIFICATION/*A*.	*USP36–NF31*	2464	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Sample solution*: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to: *Sample stock solution*: Nominally 0.1 mg/mL of amitriptyline hydrochloride in methanol from a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate. *Sample solution*: Nominally 0.01 mg/mL of amitriptyline hydrochloride from *Sample stock solution* in methanol
MINOCYCLINE *Assay* FOR INJECTION		*USP36–NF31*	4375	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Mobile phase—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer porosity. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Standard preparation*—Dissolve an accurately weighed

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution* —Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chromatograms, and measure the responses for the major peaks.
OXYCODONE AND ACETAMINOPHEN TABLETS	IDENTIFICATION/*A. Thin-Layer Chromatography*	*USP36–NF31*	4645	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Sample solution*: Change in a mixture of methanol and water (4:1). to: in a 5-mL mixture of methanol and water (4:1).
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR ORAL SOLUTION	*Assay for potassium*	*USP36–NF31*	4834	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS	*Assay*	*USP36–NF31*	4841	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Procedure: Change in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation 1* or *Assay preparation 2* instead of *Sample solution*.
ISOTRETINOIN CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 4*	*Revision Bulletin (Official October 01, 2012)*	Online	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Medium*: Change 4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide) to: 4.5% (v/v) of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lauryl dimethyl amine oxide
TROLAMINE SALICYLATE	*Assay*	*USP36–NF31*	5499	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Chromatographic system*: Change L1 to: L7
NITRIC ACID	ASSAY/ *Procedure*	*USP36–NF31*	2107	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample solution*: Change To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water. to: Weigh 2 mL of Nitric Acid in a glass-stoppered conical flask, and add 25 mL of water.
FOSPHENYTOIN SODIUM INJECTION	*Assay*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Assay preparation*: Change Transfer an

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium,
MOXIFLOXACIN OPHTHALMIC SOLUTION	*Assay*	*USP36–NF31*	4414	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 4 of *Resolution solution*: Change 0.1 mg per mg and 0.001 mg per mg, to: 0.1 mg per mL and 0.001 mg per mL,
POTASSIUM BICARBONATE EFFERVESCE	*Assay*	*USP36–NF31*	4833	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
NT TABLETS FOR ORAL SOLUTION								*solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM	*Assay*	*USP36–NF31*	4840	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORIDE FOR ORAL SOLUTION								*Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation 1* or *Assay preparation 2*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								instead of *Sample solution*.
TACROLIMUS CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5257	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 11 of USP Tacrolimus System Suitability Mixture RS: Change and tacrolimus 8-propyl analog (3*S*,4*R*,5*S*,8*S*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyri do[2,1-*c*][1,4]oxaazacycl otricosine-1,7,2 0,21-(4*H*,23*H*)-tetrone. to: and tacrolimus 8-propyl analog (3*S*,4*R*,5*S*,8*R* ,9*E*,12*S*,14*S* ,15*R*,16*S*,18*R* ,19*R*,26a*S*)-5,6,8,11,12,13 ,14,15,16,17,18, 19,24,25,26,26a -hexadecahydro -5,19-dihydroxy- 3-{(*E*)-2-[(1*R*,3*R*,4 *R*)-4-hydroxy-3-m ethoxycyclohex yl]-1-methylvinyl }-14,16-dimetho xy-4,10,12,18-te tramethyl-15,19 -epoxy-8-pro- pyl-3*H* -pyri do[2,1-*c*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								][1,4]oxaazacyclotricosine-1,7,20,21-(4*H*,23*H*)-tetrone.
BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS	APPENDIX	*USP36–NF31*	619	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change the section title *Method 6—Postcolumn DABS-Cl Derivatization* to: *Method 6—Precolumn DABS-Cl Derivatization*
VITAMIN E	SPECIFIC TESTS/*Acidity*	*USP36–NF31*	5579	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample*: Change 40 mg to: 1.0 g
FOSPHENYTOIN SODIUM	*USP Reference standards <11>*	*USP36–NF31*	3679	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to: $C_{14}H_{13}NO_2$
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION	*Assay*	*USP36–NF31*	4376	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase* and *Chromatographic system*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								—Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>).

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatographic system (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
OXYCODONE	ASSAY/	*USP36–NF31*	4648	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 7 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TEREPHTHALATE	*Procedure*							*Analysis*: Change R_U = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the *Standard solution* R_S = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the *Sample solution* to: R_U = peak response ratio of oxycodone to ethylparaben from the *Sample solution* R_S = peak response ratio of oxycodone to ethylparaben from the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Next page Next ›
- Last page Last »